Management of Gross Hematuria in Metastatic Bladder Cancer

Immediate Management and Assessment

The National Comprehensive Cancer Network recommends immediate management of gross hematuria in metastatic bladder cancer should focus on hemodynamic stabilization, bladder irrigation with continuous saline through a three-way catheter, and consideration of palliative transurethral resection of bladder tumor (TURBT) as first-line intervention, followed by palliative radiotherapy or arterial embolization if bleeding persists 1, 2
The American College of Physicians suggests that anticoagulation or antiplatelet therapy should be continued if present, as the underlying malignancy requires evaluation regardless of medication use 3

The National Comprehensive Cancer Network recommends performing palliative transurethral resection to debulk bleeding tumor tissue and achieve hemostasis, with the goal of hemostasis and symptom relief, not complete tumor resection, given the metastatic context 1, 2

The National Comprehensive Cancer Network suggests that if TURBT fails or is not feasible, palliative external beam radiotherapy (typically 20-30 Gy in 5-10 fractions) should be initiated, which achieves hemostasis in 60-80% of cases within 2-4 weeks 1, 2

The National Comprehensive Cancer Network recommends initiating or continuing systemic chemotherapy for metastatic disease if performance status allows, as tumor response may reduce bleeding, with gemcitabine/cisplatin as the preferred first-line regimen for cisplatin-eligible patients 1, 2, 4

The National Comprehensive Cancer Network notes that the critical concern for metastatic bladder cancer is prolonging quantity and maintaining quality of life, not cure, with a median survival of 12-15 months even with optimal systemic therapy 2, 4
Early palliative care consultation should be integrated to address goals of care, particularly if multiple interventions are required 1, 4

TURBT is recommended even in metastatic disease when hematuria causes clot retention or significant anemia, according to the National Comprehensive Cancer Network 5

For patients who cannot tolerate cisplatin due to renal dysfunction or other comorbidities, consider carboplatin-based regimens, as recommended by the National Comprehensive Cancer Network 6

Continue anticoagulation or antiplatelet therapy if present, as the underlying malignancy requires evaluation regardless of medication use, according to the American College of Physicians 7
Do not obtain urine cytology or urine-based tumor markers in the initial evaluation of hematuria, as they are low-yield and not recommended for this clinical scenario, according to the American College of Physicians 7
Do not defer evaluation of hematuria even if self-limited or microscopic—all gross hematuria requires urologic evaluation, according to the American College of Physicians 7
Do not use screening urinalysis for cancer detection in asymptomatic adults, according to the American College of Physicians 7

Optimal pain management should be prioritized for patients with marginal performance status and metastatic disease, according to the National Comprehensive Cancer Network 5